MTOR and hyperlipidemia: There is some evidence that pre-treatment lipid values can predict the presence, but not necessarily the severity, of hyperlipidemia associated with mTOR-inhibitor therapy, which suggests that individual factors (genetic, co-morbid, or otherwise) may contribute to the risk of severe increases (55).